In compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, (‘PIT Regulations’) and as per the Company's ‘Code of Conduct’, Syschem (India) has informed that the trading window for dealing in the securities of the Company shall remain closed for Directors/officers/Designated Persons and their immediate relatives as defined under the PIT Regulations and the said code, from Tuesday, October 01, 2024 till the expiry of 48 hours after the announcement of unaudited financial results of the company for the quarter ended on 30th September, 2024. The dates of the meeting of the Board of Directors of the Company to approve the unaudited financial results of the Company for the quarter ended 30th September, 2024 will be intimated in due course.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: